

Toll-like receptors as therapeutic targets in cystic fibrosis.

AUTHOR(S)

Catherine M. Greene, Peter Branagan, Noel G. McElvaney

CITATION

Greene, Catherine M.; Branagan, Peter; McElvaney, Noel G. (2008): Toll-like receptors as therapeutic targets in cystic fibrosis.. Royal College of Surgeons in Ireland. Journal contribution.
<https://hdl.handle.net/10779/rcsi.10783976.v1>

HANDLE

[10779/rcsi.10783976.v1](https://hdl.handle.net/10779/rcsi.10783976.v1)

LICENCE

CC BY-NC-ND 4.0

This work is made available under the above open licence by RCSI and has been printed from <https://repository.rcsi.com>. For more information please contact repository@rcsi.com

URL

https://repository.rcsi.com/articles/journal_contribution/Toll-like_receptors_as_therapeutic_targets_in_cystic_fibrosis_/10783976/1

Expert Opinion

1. Introduction
2. Infection and inflammation in the pathophysiology of CF
3. TLR expression and function
4. TLR signalling pathways
5. TLR agonists in the CF lung
6. Targeting TLRs in CF
7. Delivery of therapeutics to the CF lung
8. Current therapeutics and their effect on TLRs
9. Concluding remarks
10. Expert opinion

informa
healthcare

Anti-inflammatory

Toll-like receptors as therapeutic targets in cystic fibrosis

Catherine M Greene[†], Peter Branagan & Noel G McElvaney

Beaumont Hospital, Education and Research Centre, Respiratory Research Division, Royal College of Surgeons in Ireland, 9 Dublin, Ireland

Background: Toll-like receptors (TLRs) are pattern recognition receptors that act as a first-line of defence in the innate immune response by recognising and responding to conserved molecular patterns in microbial factors and endogenous danger signals. Cystic fibrosis (CF)-affected airways represent a milieu potentially rich in TLR agonists and the chronic inflammatory phenotype evident in CF airway epithelial cells is probably due in large part to activation of TLRs. **Objective/methods:** To examine the prospects of developing novel therapies for CF by targeting TLRs. We outline the expression and function of TLRs and explore the therapeutic potential of naturally-occurring and synthetic TLR inhibitors for CF. **Results/conclusion:** Modulation of TLRs has therapeutic potential for the inflammatory lung manifestations of CF.

Keywords: cystic fibrosis, inflammation, innate immunity, therapeutics, toll-like receptors

Expert Opin. Ther. Targets (2008) 12(12):1-15

1. Introduction

The innate immune system plays a key role in regulating responses to infection and inflammation in the pathophysiology of cystic fibrosis (CF). Toll-like receptors (TLR) are important components of innate immunity that are activated in response to both infective and inflammatory stimuli. Here we focus on the current paradigm regarding the function of TLRs. The important roles of each member of the TLR family in regulating pro-inflammatory gene expression in response to microbial and endogenous agonists in the CF lung is addressed. The major signalling pathways activated by TLRs are explained and methods to target either TLRs or their signalling pathways using microbial and naturally-occurring endogenous inhibitors or antiproteases are described. Current treatment regimens and how they may affect TLR function in the CF lung are also discussed.

2. Infection and inflammation in the pathophysiology of CF

CF is caused by mutations of the CF transmembrane conductance regulator (CFTR) gene. It is a lethal hereditary disorder that is relatively common in Europe and North America, accounting for 1 in 3000 live births. Amongst Caucasians, 1 in 20 is a heterozygotic carrier of a mutant CFTR allele. Other races including Hispanics, Blacks and Asians are also affected but in smaller numbers [1]. The clinical consequences of CF are protean with multiple organs potentially being involved. The liver, pancreas and intestinal tract can all be affected, however the major causes of morbidity and mortality are the lung disease [2]. This is characterised by chronic airway infections with *Pseudomonas*, *Staphylococcus*, *Haemophilus*, *Aspergillus* and *Burkholderia* species, overproduction of thick mucus and inflammation [2,3]. Other complications of CF affecting the airways can include haemoptysis, pneumothorax, pulmonary hypertension and *cor pulmonale*

Although improvements in healthcare have enhanced survival the outlook for individuals with CF could be better.

The lung disease in CF is characterised by infection/colonization, inflammation and mucus overproduction [4]. Inflammation in CF is to a large extent compartmentalised to the lung epithelial surface and represents an interaction between bacteria, inflammatory cells, their secretions and epithelial cells and their receptors. It also represents an inability of the lung's innate defences to clear the infective causes of inflammation. Historically the lung has been perceived as an organ primarily involved in gas exchange. However, due to its unique relationship with the environment, the lung must defend itself from infection by numerous inhaled micro-organisms. Various innate defences protect the lung from infection, including the cough reflex, the mucociliary escalator, and the intrinsic antimicrobial properties of the mucosal surface. In addition, an extensive alveolar-capillary membrane containing immune and non-immune cells is exposed to microbial challenges. As a result, pulmonary tissues generate a brisk innate host response to both inhaled and haematogenous pathogens in order to clear the offending microorganism and preserve gaseous exchange. Innate immunity plays a key role in these events in the CF lung.

3. TLR expression and function

The TLR family represent a conserved and increasingly well-characterised group of pattern recognition receptors (PRRs). TLRs constitute the most significant component of pulmonary PRRs and can recognize and discriminate a diverse array of microbial antigens. The family comprises a selection of transmembrane proteins that constitute an important unit of the innate immune system. TLR expression is widespread and includes, but is not limited to, cells of myeloid and lymphoid origin, endothelial and epithelial cells.

First identified in the fruitfly *Drosophila melanogaster*, the *Drosophila* or dToll was initially characterised as a factor regulating embryogenic –ventral axis formation. Later dToll was shown to act as a key receptor regulating antimicrobial defense in the adult fly [5]. In 1991 Gay and Keith reported the identification of structural and functional similarities between dToll and the mammalian Type I IL-1 receptor (IL-1RI) [6] an important receptor in innate immunity. This prompted a surge of research leading to the identification and partial characterisation of ten human TLRs sharing sequence similarity with the cytosolic signalling domain of IL-1RI.

TLRs are germ-line-encoded pattern recognition receptors. Each has a role in the innate immune response [7]. An extracellular leucine-rich repeat (LRR) ligand recognition domain and an intracellular signalling domain integrating the functional signature motif of TLRs, the so-called TIR (Toll/interleukin-1 receptor) domain, characterises all of the TLR type I transmembrane proteins. The conserved cytosolic TIR domain consists of up to 200 amino acids [8,9] essential for signalling whilst the external LRR motifs probably confer

specificity to TLRs with respect to their pattern recognition properties [10]. TLR4, the mammalian lipopolysaccharide (LPS) receptor, was the first mammalian TLR to be identified. Its properties were elucidated from studies on the LPS hyporesponsive mouse strain C3H/HeJ [11] which have a dominant-negative Pro712His mutation in the TIR domain of their TLR4 and are resistant to challenges with lethal doses of LPS.

TLRs facilitate the recognition and discrimination of invading microbes and induce an appropriate immune response. They are activated by specific microbial agonists including ones derived from bacteria, viruses, mycoplasma, yeasts and protozoa (Figure 1). TLR4, the principal receptor for Gram-negative LPS can also recognise other microbial agonists including respiratory syncytial virus (RSV) [12], *Chlamydia pneumoniae*, Hsp60, flavolipin and murine retroviruses F protein [13-16]. Interestingly a number of endogenous signals can also activate TLR4 and other TLRs including hyaluronan and neutrophil elastase (see below) [17,18].

TLR2 appears to recognize a broad repertoire of agonists and is a functionally important PRR in the airways, which can respond to lipoteichoic acid, peptidoglycan and *M. pneumoniae* [19-21]. As a dimer with other TLRs, TLR2 confers responsiveness to a selection of agonists [22]. For example, with TLR1 it recognizes triacylated lipopeptides, Gram-positive lipoteichoic acid and *Streptococcus pneumoniae* [23], whereas with TLR6 it recognises diacylated lipopeptides [24]. There has been a single report of TLR2's involvement in the response to flagellin [25].

TLRs 3, 7, 8 and 9 have roles in the recognition of nucleic acids. TLR3 responds to double-stranded (ds)RNA [26,27] a potential by-product in virally infected cells. TLRs 7 and 8, although not well expressed by lung epithelium [28] are expressed by immune cells within the lung and have a known role in the antiviral response [29,30]. Their major agonists are guanosine- and uridine-rich single-stranded (ss)RNA found in many viruses [31,32]. Microbial DNA featuring unmethylated CpG (uCpG) dinucleotides motifs activate TLR9 [33]. These occur frequently in bacterial but not mammalian DNA.

Flagellin is a protein subunit of bacterial flagellae expressed by Gram-negative bacteria. It can induce TLR5-dependent signalling [34]. Airway epithelial cells utilise TLR5 in their responses to *Pseudomonas aeruginosa*, *Legionella pneumophila* and *Bordetella bronchiseptica* [35-38]. TLR10 is an orphan member of the human TLR family [39].

4. TLR signalling pathways

An important feature of TLR signal transduction is that highly conserved pathways can be activated by the different TLRs. Thus, both TLRs and their intracellular signalling molecules represent key inhibitory targets for therapeutic drug design.

Activation of TLRs can lead to downstream signalling cascades resulting in the activation of pro-inflammatory gene transcription. These TLR-mediated changes in gene expression are critically dependent on the cytosolic TIR domain [7,40].




Figure 1. Microbial Toll like receptor (TLR) agonists.

dsRNA: Double-stranded RNA; hTLR: Human TLR; LPS: Lipopolysaccharide; mTLR: Murine TLR; ssRNA: Single-stranded RNA; uCpG: Unmethylated CpG dinucleotide motifs.

TLRs provide a scaffold for protein-protein interactions most notably those leading to the activation of NF- κ B and the interferon regulatory factors (IRFs) [41,42]. Activation of AP1 and the MAPKs jun N-terminal kinase (JNK), p38 and extracellular signal-regulated kinase (ERK)1/2 [43] are other classical signals regulated by TLR signalling.

Agonist-induced homo- or heterodimerisation of TLRs represents the first step in all TLR signalling cascades. TLR4 uniquely requires two accessory proteins for full responsiveness to its agonists; myeloid differentiation protein-2 (MD-20, a soluble glycoprotein on the outer surface of the cell membrane [44] and CD14, a glycoposphatidyl inositol-anchored receptor which binds to LPS-LPS-binding protein complexes [45]. NF- κ B activation by TLRs then occurs in response to recruitment of TIR-domain-containing adaptor proteins that interact with the TIR domains of TLRs. Four TIR adaptor proteins MyD88 [46], MyD88-adpater like (Mal)/TIRAP [47,48], TIR domain containing adaptor inducing IFN- β (TRIF) [42,49] and TRIF-related adapter molecule (TRAM) [50-52] integrate TLR activation with downstream signalling. MyD88 transduces signals for all TLRs with the exception of TLR3, which utilises TRIF instead, whilst TRAM and Mal are involved in TLR3 and TLR2/4 signalling, respectively.

Following its recruitment MyD88 associates with IL-1 receptor-associated kinase-4 (IRAK-4) (Figure 2A) [53]. A series of protein-protein interactions then assemble involving IRAK-1, TNF receptor-associated factor 6 (TRAF6), TGF- β -activated kinase-1 (TAK1) and TAK1-binding proteins, TAB1 and TAB2. Ubiquitin conjugating enzyme (Ubc)13 and ubiquitin-conjugating enzyme E2 variant 1A (Uev1A), next catalyse the synthesis of a polyubiquitin chain on TRAF6 [54] triggering activation of TAK1 by phosphorylation. Activation of the I κ B kinase (IKK) complex (IKK α , IKK β and NF- κ B essential modulator (NEMO)/IKK γ) [55], ensues culminating in phosphorylation, ubiquitylation and proteosomal degradation of I κ B and nuclear translocation of NF κ B.

Signalling from TLR3 or TLR4 via TRIF and TRAM can also trigger a signalling pathway leading to expression of the type I interferons. This pathway involves the non-canonical

IKKs, TANK-binding kinase 1 (TBK1) and IKK ϵ /IKK ι and culminates in activation of the transcription factors IRF 3 and 7 (Figure 2B) [50,56,57] which regulate IFN- β and IFN- α expression, respectively.

TLRs expressed by immune and epithelial cells in the CF lung contribute to the pulmonary immune response by regulating the production and secretion of chemokines, cytokines and antimicrobial peptides and by enhancing cell surface adhesion molecules expression. Surface expression of intercellular adhesion molecule 1 (ICAM-1) can be increased on airway epithelial cells in response to triacylated lipopeptide, LPS, uCpG DNA, dsRNA and Influenza virus A [58,59]. Multiple pro-inflammatory cytokines can be regulated by TLR activation in these cells. TLR2, TLR4 and TLR9 agonists upregulate IL-8, TNF- α and IL-6 amongst others [58,60-62]. IL-8 is a potent neutrophil chemoattractant and a key factor regulating the neutrophil-dominated airway inflammation characteristic of CF. The expression of other chemokines by airway epithelial cells however is also regulated by TLR agonists that activate TLRs 2-5. Macrophage inflammatory protein 3 (MIP-3) expression, for example, is increased in response to zymosan, dsRNA, LPS and flagellin [63].

The human β -defensins (HBD) are antimicrobial peptides produced by epithelial cells. TLR2 activation by bacterial lipoprotein enhances HBD2 expression in tracheobronchial epithelium [64] whilst lipoteichoic acid and peptidoglycan are also known to induce TLR2-mediated increases in HBD2 expression in a variety of airway epithelial cells [61,65]. TLR4 agonists, including neutrophil elastase, similarly regulate HBD2 expression in both immortalized and primary airway epithelial cells [66].

In addition to microbial agonists, a number of host-derived factors with TLR-activation properties have been described. Endogenous agonists with activity against TLR2 or TLR4 include neutrophil elastase, hyaluronan, heat-shock proteins, oxidants and fibronectin amongst others [17,18,67-72]. Stimulation of TLRs by these danger-associated molecular patterns (DAMPs) points to the existence of mechanisms whereby TLRs can recognise host molecular patterns that represent a danger signal due to chronic inflammation [73].




Figure 2. Toll like receptor (TLR) signalling cascades leading to NF-κB or interferon regulatory factor IRF activation.

A. Following triggering of TLRs 1, 2 and 4-9 the Toll/IL-1R (TIR) domains of TLRs and myeloid differentiation factor 88 (MyD88) interact. The signal is transduced via interleukin-1 receptor associated kinase (IRAK)-4, IRAK-1 and TNF receptor-associated factor 6 (TRAF-6). Next TRAF6 is ubiquitinated by the E2 ligases ubiquitin conjugating enzyme 13 (Ubc13) and ubiquitin-conjugating enzyme E2 variant 1A (Uev1A). This activates transforming growth factor-β-activated kinase-1 (TAK1), which associates with TAK1-binding protein (TAB)1/TAB2 leading to phosphorylation and activation of the IκB kinase (IKK) complex, culminating in activation NFκB which can then translocate to the nucleus to regulate gene expression. TLR2 or TLR4 can also activate the IKK complex indirectly via MyD88 adaptor-like (Mal)/MyD88.

B. TLR3 and TLR4 activate IKKε and TBK1 via TIR domain-containing adaptor inducing interferon-β (TRIF)/TRIF-related adaptor molecule (TRAM) leading to interferon regulatory factor (IRF)3 and IRF7 activation and production of interferon-β and -α. TLR3 can also activate the IKK complex via TRIF, leading to classical NF-κB activation.

TBK1: TANK-binding kinase 1.

5. TLR agonists in the CF lung

The CF lung represents a milieu that is potentially rich in a variety of microbial (Figure 1) and endogenous TLR agonists. It is widely accepted that there are higher than normal levels of neutrophil elastase in CF bronchoalveolar lavage fluid whilst the presence of both bacterial and yeast-derived factors has also been demonstrated [74]. For example *Pseudomonas* DNA has been detected in CF sputum and bronchoalveolar lavage fluid [58,75] flagellin expressed by planktonic *Pseudomonas* may act as a TLR5 agonist in early colonisation and LPS is also likely to be present at high levels in the CF lung. TLR2 agonists such as microbial lipopeptides or lipoteichoic acids (LTA) derived from *Pseudomonas* and/or *Staphylococcus* species or fungal-derived factors are other potential candidates. Viruses express agonists for TLRs 3, 7 and 8, and viral infections in CF have the potential to modulate TLR activity.

5.1 The role of viral infection in CF

Increasing interest is focusing on the role of viral infections in CF in predisposing to bacterial superinfection and as

independent pulmonary pathogens. Up to 40% of pulmonary exacerbations are attributed to viruses in individuals with CF [76-78] and are associated with a persistent decrease in lung function [76,78-80], prolonged hospital admission and increased likelihood of earlier acquisition of *Pseudomonas aeruginosa* colonization [80,81]. A distinction between upper and lower respiratory tract viral infections exists and in CF, increased incidences of lower respiratory tract viral infections are associated with poorer outcomes [79].

Viral infection can increase expression of IL-8 thus exaggerating the inflammatory cascade [82]. The co-existence of bacterial pathogens can also further predispose to epithelial cell damage as part of the inflammatory process, with resultant increased transepithelial permeability [83]. Influenza A infection has been associated with neutrophil infiltration [84] and both influenza and adenovirus have cytotoxic effects on airway epithelial cells [85]. *In vitro* studies suggest that viruses promote increased bacterial adherence to the airways [86,87]. On a molecular level it would appear that viral infection interferes with TLR responses. In response to rhinovirus human alveolar macrophages showed an impairment of

cytokine responses to bacterial LPS and LTA [88] thus a more thorough investigation of the dynamics of innate immunity in CF in the context of both bacterial and viral infection is warranted.

Prevention and therapeutic strategies for viral infection have proven controversial. A Cochrane Review from 2000 showed no increased protection with influenza vaccine in individuals with CF [89]; conversely a recent trial has shown this may not be the case [90]. Despite this the vaccine has been shown to be safe and is currently recommended for individuals with CF. Palivizumab a monoclonal antibody to RSV, has been developed for passive immunoprophylaxis and has shown some promise. However, there is currently no RSV vaccine.

The focus of research has recently swung towards antiviral therapy to limit the inflammatory response, with limited results to date. Ribavirin, a nucleotide analogue, is licensed for RSV infection but not in CF, and results have been variable. The neuraminidase inhibitors oseltamivir and zanamavir, if used early, may be effective for the treatment and prophylaxis of influenza infection, and are safe to use. The adamantanes, amantadine and rimantadine, are not generally used, and resistance rates with these for influenza A of up to 92% have been reported [91,92].

Developing newer strategies for therapy necessitates evaluation of more defined viral signalling pathways, and should possibly focus on TLR involvement. Viruses detectable in CF secretions during exacerbations act mainly through TLR3 (influenza A, influenza B, rhinovirus). Signalling pathways for parainfluenza virus via TLRs are undetermined whereas RSV has been shown to act through TLR4 [14].

6. Targeting TLRs in CF

There are a variety of potential strategies available to interfere with TLR function in the CF lung. These include traditional approaches such as the use of inhibitory peptides, pharmacological methods to promote the expression of endogenous anti-TLR molecules or administration of purified versions of these molecules. Exploring the therapeutic properties of naturally-occurring TLR antagonists is an area that is also likely to have merit.

6.1 Endogenous inhibitors

Like the autocrine mechanisms that exist to control regulation of TNF and IL-1 signalling, a number of endogenous TLR inhibitors have been identified that can negatively regulate TLR signalling processes. The factors that we will consider here are A20, toll interacting protein (Tollip), single immunoglobulin IL-1-related receptor (SIGIRR), MyD88s, IRAK-M, suppressors of cytokine synthesis (SOCS), sterile α and HEAT-Armadillo motifs protein (SARM), Src homolog protein tyrosine phosphatase 1 (Shp-1), protein tyrosine phosphatase, non-receptor type 1 (PTP1B), mucin 1 (MUC1) and peroxisome proliferator activated receptor

gamma (PPARgamma) (Table 1). This diverse range of molecules includes transmembrane proteins and nuclear receptors, ubiquitin-modifying and adaptor proteins, kinases and phosphatases. Although each of these proteins can function to control TLR signalling, their mode of action differs; nonetheless, they can commonly be grouped as TLR inhibitors.

A20 is a ubiquitin-modifying enzyme and zinc-finger protein that was first reported to regulate TLR4 signalling [93,94]. It is now known that A20 can suppress both TLR2- and TLR4-induced IL-8 expression in airway epithelial cells and can be upregulated by measles P virus protein [95]. Tollip is an inhibitor of both IL-1 and LPS signalling [96]. Inhibition by Tollip is mediated through its ability to block the activity of IRAK after TLR activation [97]. Like Tollip, the TIR family member TIR8, also known as SIGIRR, is a negative regulator of IL-1 and TLR signalling [98]. An alternatively spliced form of MyD88 exists, termed MyD88s. This variant is unable to recruit IRAK-4 and thus transcriptionally controls negative regulation of innate immune responses to MyD88-dependent TLRs [99]. IRAK-M is a novel member of the IRAK family [100] and a negative regulator of TLR signalling [101]. It has an important role in endotoxin tolerance and its expression is restricted to monocytes and macrophages. The SOCS proteins are induced by stimulation of TLRs and both SOCS1 and 3 have been shown to have the ability to suppress TLR signalling. Rothlin *et al.* [102] uncovered the complex negative feedback mechanism limiting TLR signalling involving the Tyro3/Axl/Mer (TAM) family of receptor tyrosine kinases, which induce expression of the inhibitory proteins SOCS1 and SOCS3.

MyD88, Mal, TRIF and TRAM are the four TIR adaptors associated with TLR-activation functions. The fifth known TIR adaptor, SARM, acts as a negative regulator of TRIF-dependent TLR signalling and thus can impair TLR3 and TLR4 responses [103]. Recently SHP-1 [104] and PTP1B [105] have been identified as phosphatases that can negatively regulate TLR-mediated production of pro-inflammatory cytokines by inhibiting activation of the transcription factors NF- κ B and MAPK (and IRFs for PTP1B). Interestingly, SHP-1 concomitantly increases the production of type I interferon mediated by TLRs by directly binding to and inhibiting activation of IRAK1. Thus, SHP-1 appears to have an important role in skewing the balance between expression of pro-inflammatory cytokines and type I interferons in the innate immune response [104].

MUC1 is a transmembrane glycoprotein expressed by airway and other epithelial cells. Recently, it has been shown to have an anti-inflammatory role particularly with respect to *Pseudomonas aeruginosa* or its flagellin but also against TLR2, 3, 4, 7 and 9 agonists [106,107]. 15deoxy-prostaglandin-J2 and troglitazone are natural and synthetic PPARgamma agonists. Their activation of PPAR-gamma can result in reduced stimulation of DCs via the ligands for TLR 2, 3, 4 and 7 [108].

Table 1. Endogenous Toll like receptor (TLR) inhibitors.

Protein	Signalling target	Ref.
A20	TLR2, TLR4	[21,93-95]
Tollip	TLR4 (and IL-1R) at IRAK1	[96,97]
SIGIRR	TLR4 (and IL-1R)	[98]
MyD88s	TLR4 (and IL-1R) Myd88-dependent signalling	[99]
IRAK-M	TLR2, TLR4	[100,101]
SOCS1/3	TLRs	[102]
SARM	TLR3, TLR4, TRIF-dependent signalling	[103]
Shp-1	TLR3, TLR4 at IRAK1	[104]
PTP1B	TLRs, MyD88- and TRIF-dependent signalling	[105]
MUC1	TLR2, TLR3, TLR4, TLR5, TLR7, TLR9	[106,107]
PPAR γ	TLR2, TLR3, TLR4, TLR7	[108]

IRAK: Interleukin-1 receptor associated kinase; MyD88: Myeloid differentiation factor 88; MUC1: Mucin 1; PPAR γ : Peroxisome proliferator activated receptor gamma; PTP1B: Protein tyrosine phosphatase; non-receptor type 1; SARM: Sterile α and HEAT-Armadillo motifs; Shp-1: Src homolog protein tyrosing phosphatase 1; SIGIRR: Single immunoglobulin IL-1-related receptor; SOCS: Suppressors of cytokine synthesis; Tollip: Toll interacting protein; TRIF: TIR domain-containing adaptor inducing interferon- β .

6.2 Microbial TLR antagonists

In addition to naturally-occurring endogenous TLR inhibitors, there exist in nature a number of microbial TLR antagonists that may have therapeutic potential for CF (Table 2). To date a selection of such microbial proteins have been discovered and partially characterised. These include the viral proteins A46R, A52R and N1L from *Vaccinia* virus and RSV G/soluble G protein [109-112] and the TIR domain-containing-proteins typhimurium large plasmid A (TlpA) from *Salmonella*, *Brucella* TIR-containing protein 1 (Btp1)/TIR domain containing-protein (Tcp)B from *Brucella* spp. and TcpC from *Escherichia coli* [113-115].

A46R and A52R share amino acid sequence similarity with the mammalian TIR domain and can interfere specifically with IL-1 signal transduction [109]. Ectopic expression of A46R can inhibit intracellular signalling by a range of TLRs. It targets all four host TIR adaptors MyD88, Mal, TRIF and TRAM, and interferes with downstream activation of NF κ B and MAPKs. A46R also disrupts TRIF-induced IRF3 activation and induction of regulated upon activation, normally T-expressed, and presumably secreted (RANTES) [110]. A46R is functionally distinct from the other described *Vaccinia* virus TLR inhibitor, A52R which can potently block both IL-1- and TLR4-mediated NF- κ B activation. A52R mimics the dominant-negative effect of a truncated version of MyD88 on IL-1, TLR4 and IL-18 signalling but has no effect on MyD88-independent signalling pathways.

Together A46R and A52R are used by *Vaccinia* virus to suppress TIR domain-dependent intracellular signalling. Of particular interest here is the demonstration that either A46R or A52R, like dominant negative versions of MyD88 and Mal can interfere with the intracellular mechanisms by which neutrophil elastase upregulates inflammatory gene expression in both primary and transformed bronchial epithelial cells [60].

Bioinformatics has identified a third *Vaccinia* virus protein, N1L, which shares significant similarity with A52R [111]. N1L protein strongly affects *Vaccinia* virulence *in vivo* by suppressing NF- κ B and IRF3 activation following engagement TLRs. N1L also disrupts signalling to NF- κ B by the TNF superfamily of receptors by targeting the IKK complex for inhibition.

RSV infection of monocyte-derived dendritic cells (mDCs) leads to activation of the IFN-inducing pathway leading to type I IFN induction. Having shown that RSV initial attachment to cells can block polyI:C-mediated IFN-beta induction Shingai *et al.* [112] further demonstrated that polyI:C- or LPS-mediated IFN-beta production were inhibited by RSV G or soluble G (sG) proteins. These anti-TLR3/4 effects were mediated via the TRIF pathway and suppressed the production of IFN-beta. The exact molecular mechanism by which this inhibition occurs remains to be determined.

Like viruses, pathogenic bacteria have evolved sophisticated molecular strategies to subvert host defenses. Btp1 is a 250 aa protein expressed by *Brucella abortus* that contains a C-terminal 130-amino acid domain with significant sequence similarity to the TIR domains of TLR2, TLR4, SIGIRR and MyD88. This similarity exists both in box 1, the signature sequence of the TLR family, and in box 2 which is important for signalling [114]. Btp1 shares homology with TlpA, a *Salmonella* effector that interferes with TLR signalling *in vitro* [113]. Ciril *et al.* have also identified a mechanism by which virulent bacteria can interfere directly with TLR function by secreting proteins that act as inhibitory homologs of the mammalian TIR domain [115]. In addition to the TIR domain containing-protein (Tcp) TcpB from *B. melitensis* this group also identified a gene encoding a Tcp in *Escherichia coli* CFT073 (TcpC). *In silico* analysis predicts significant tertiary structure homology between these proteins and the TIR domain of human TLR1. Tcps can directly bind to MyD88, impede TLR signalling and suppress innate immunity.

6.3 Inhibitory peptides

Peptide mimetics that can inhibit agonist binding or signal transduction are appealing therapeutic agents for CF. In addition to their well-defined specificity, peptides can be engineered to gain access to intracellular compartments and thus directly interfere with signalling pathways. As a class, these low-molecular-weight compounds have significant anti-inflammatory potential. To date just a few peptide-blocking studies targeting TLRs have been published. Bartfai *et al.*

Table 2. Microbial Toll like receptor (TLR) antagonists.

Protein	Organism	Target	Ref.
A46R	Vaccinia virus	TLR3, TLR4 at TRIF, TRAM, MyD88, Mal	[109,110]
A52R	Vaccinia virus	TLR4 (IL-1, IL-18)	[109,110]
N1L	Vaccinia virus	TLR2, TLR3, TLR4 at IKK complex	[111]
RSV sG	RSV	TLR3, TLR4	[112]
TlpA	<i>Salmonella enterica</i> serovar Enteritidis	TLR4 (IL-1) at MyD88	[113]
Btp1	<i>Brucella abortus</i>	TLR2	[114]
TcpP	<i>Brucella melitensis</i>	TLRs at MyD88	[115]
TcpC	<i>Escherichia coli</i>	TLRs at MyD88	[115]

Btp1: *Brucella* TIR-containing protein 1; IKK: I κ B kinase; Mal: MyD88 adaptor-like; MyD88: Myeloid differentiation factor 88; RSV: Respiratory syncytial virus; TlpA: Typhimurium large plasmid A; Tcp: TIR domain containing-protein; TRAM: TRIF-related adaptor molecule; TRIF: TIR domain-containing adaptor inducing interferon- β .

designed and synthesized a low molecular weight MyD88 mimic, hydrocinnamoyl-L-valyl pyrrolidine, modeled on a tripeptide sequence of the BB-loop [(F/Y)-(V/L/I)-(P/G)] of the TIR domain. Examination of its pharmacological effects focussed on its ability to inhibit IL-1- rather than TLR-mediated events but did indicate a concentration-dependent inhibitory capacity against IL-1-induced phospho-rylation of p38 MAPK in murine lymphocytes. *In vivo*, this cell-penetrating TIR domain mimic also significantly attenuated IL-1-induced fever. Davies *et al.* [117] also tested TIR mimetics based on MyD88, whilst Toshchakov and Vogel [118] performed a comprehensive study using a set of blocking peptides comprised of the 14 aa corresponding to the sequences of the BB loops of MyD88, Mal, TRIF and TRAM linked to the cell-penetrating segment of the *Antennapedia* homeodomain. TLR4-mediated changes in gene expression, as well as MAPK and transcription factor activation associated with both MyD88-dependent and -independent signalling pathways, were disrupted. All four peptides success-fully disrupted TLR4-mediated responses whilst TLR2 responses were less well inhibited with the exception of a modest effect of the MyD88 peptide on triacylated lipopeptide-induced IL-1 β mRNA. The data suggest that the adapter BB loops of different MyD88 adaptor proteins may serve distinct roles in TLR4 and TLR2 signalosome assembly. This specificity is likely to determine the effectiveness of developing TIR-based peptides as anti-inflammatory drugs.

6.4 Anti-TLR properties of pulmonary antiprotease

Although classically regarded as antiproteases, secretory leukoprotease inhibitor (SLPI), elafin, and alpha-1 antitrypsin (A1AT) also function as antimicrobial agents. Each has potential anti-TLR activity.

6.4.1 *Slpi*

SLPI is an 11.7 kDa protein, secreted by airway epithelial cells [119]. Along with A1AT, it comprises the body's major antineutrophil elastase defence [120]. As an antiprotease, it has been shown to protect tissue locally by inhibiting other proteases such as trypsin, chymotrypsin, chymase, tryptase and cathepsin G [121]. In addition to its antiprotease actions SLPI has been shown to have anti-infective and anti-inflammatory properties [122]. It displays antimicrobial action against *Pseudomonas aeruginosa*, *Staphylococcus aureus* and *Candida albicans* [123,124]. Other studies have also demonstrated its anti HIV properties [125].

With respect to targeting TLRs, SLPI has been shown to inhibit TLR- induced cytokine expression, impairing TLR2- and TLR4-mediated responses in monocytic cells. In the setting of CF, bacterial colonization and persistent infection, particularly with *Pseudomonas aeruginosa* is one of the main determinants of morbidity and mortality in patients, thus inhibition of TLR2- and TLR4-mediated responses by SLPI underlines its therapeutic potential in this area [126]. Interestingly LPS is known to upregulate SLPI production in macrophages suggesting the existence of a novel endogenous negative feedback loop [127].

The mechanisms by which SLPI interferes with LPS effects are dependent on its antiprotease activity and involve impairing degradation of I κ B α without affecting phosphorylation or ubiquitination [128] and by binding directly to p65 NF κ B binding sites in a site-specific manner [129].

SLPI as an anti fungal is also of potential importance in the CF population. *Aspergillus* colonization is associated with accelerated lung function decline and poorer overall outcomes. Recombinant SLPI (rSLPI) has been shown to dose-dependently kill hydrated but not airborne conidia [130]. The same group found a partial inhibition of fungal protease activity (*A. fumigatus* virulence factor) by rSLPI, and this also inhibited the induction of the pro-inflammatory cytokine response in airway epithelial cell lines [131].

Excessive mucus production as a result of an exacerbation of CF is a huge symptomatic problem for the patient, particularly when difficult to expectorate, and leads to increased patient anxiety, as well as detrimental effects on lung function and worsening respiratory failure. SLPI's potential as an antimucin agent in CF has also been highlighted [132] in a study that demonstrated its inhibitory capacity against TLR2, TLR4 and TLR9 agonist-induced MUC2 and 5AC expression via a mechanism primarily dependent on the inhibition of TGF- α release. SLPI may therefore have a potential role as an antimucin agent in CF.

6.4.2 *Elafin*

Elafin is a 6 kDa serine antiprotease expressed in mucosal surfaces [133]. Pre-elafin, also known as trappin 2, is its precursor which undergoes proteolytic cleavage to release

mature elafin [134]. There is increasing interest in this anti-protease as an immunomodulatory molecule. Cytokine-mediated increases in elafin production by epithelial cells are greater than the increase in SLPI production [135], and it has been suggested that elafin is of greater significance during an inflammatory challenge to the lungs. Antimicrobial properties have been described for elafin against *Pseudomonas aeruginosa* and *Staphylococcus aureus* [123].

As an anti-inflammatory agent elafin can inhibit LPS-induced production of monocyte chemoattractant protein 1 (MCP-1) in monocytes. This effect is mediated via impairment of both AP-1 and NF- κ B activation, via an effect on the ubiquitin-proteasome pathway [136]. Elafin also has anti-fungal properties [137]. Thus, like SLPI, elafin may hold therapeutic promise in the treatment of inflammation and infection in CF.

6.4.3 A1at

A1AT is the body's most abundant serine antiprotease. Increasing evidence exists to suggest that A1AT possesses properties other than its antiprotease function including both anti-inflammatory and immunomodulatory effects. For example native, polymerised or oxidised A1AT can inhibit LPS-stimulated synthesis of TNF- α and IL-1 β whilst enhancing the release of the anti-inflammatory cytokine IL-10 [138]. Whether A1AT has direct anti-TLR4 activity remains to be shown, however, C-36 peptide, a degradation product of A1AT, also has potential LPS-modulatory activity against human monocytes [139].

7. Delivery of therapeutics to the CF lung

A major hurdle in targeting therapeutics to treat the pulmonary inflammatory manifestations of CF is the effective delivery of an agent to the lung. The presence of biofilm, excessive mucus and parenchymal damage in the CF lung can negatively affect drug distribution and bioavailability. Whilst aerosol delivery ensures direct administration to the site of action and less systemic toxicity, its drawbacks include problems in sampling of epithelial lining fluid to quantify anti-inflammatory effects and determine pharmacokinetics. An ideal aerosolised therapeutic agent for CF should be sterile, nonpyrogenic, chemically stable and have a particle size ranging from 1 to 5 μ m for reproducible drug delivery to the airways [140,141]. The drug should have a wide margin of dosage safety to allow for the varying conditions in the lungs of CF patients and should be easily nebulised.

8. Current therapeutics and their effect on TLRs

Continuous cycles of infection lead to increased morbidity and mortality in the setting of CF. Prompt antibiotic therapy based on appropriate sensitivities is associated with reduced decline in lung function and improved patient outcomes. Symptomatically, inhaled/nebulised broncho-dilator therapy

provides relief from breathlessness, and mucolytic therapy can be very useful in enabling patients to expectorate sputum. There is increasing focus on therapy targeting the underlying pathogenesis, and in particular underlying inflammation.

8.1 Anti-inflammatory therapies

The underlying inflammatory state is central to the disease process, and many therapies have been initiated in an effort to counter this, including NSAID's, steroids, and, more recently azithromycin. Initial studies looking at diffuse pan bronchiolitis in Japan showed improvement with macrolide therapy [142]. Studies in CF have shown similar improvements, with improved forced expiratory volume in one second (FEV1), reduced number of hospital admissions, increased weight, and improved quality of life [143-145]. Azithromycin is a macrolide antibiotic, and in addition to its antibacterial properties which may include effects on biofilm formation, may have anti inflammatory [146] and immunomodulatory effects.

For example, azithromycin has been shown to reduce TNF- α levels in CF airway epithelial cells [147] and to suppress activation of NF- κ B and pro inflammatory cytokine expression in tracheal aspirate cells from premature infants [148]. Some evidence exists for TLR4- and TLR5-specific properties of azithromycin. An experimental model has shown that azithromycin attenuates the effects of LPS administration in mice [149]. Azithromycin has been shown to reduce expression of *Pseudomonas aeruginosa* flagellin [150,151]. A more recent model, with *Salmonella typhimurium*, has shown that azithromycin inhibits the formation of flagellar filaments without suppressing flagellin synthesis [152].

Glucocorticoids are well documented as anti inflammatory agents but chronic use is associated with long-term sequelae including osteoporosis, peptic ulcer disease and cataracts. Their mechanism of action is associated with upregulation of TLRs although they can impair the differentiation and antigen presenting ability of dendritic cells [153].

8.2 Mucolytic therapies

Nebulised hypertonic saline has been shown to be useful for sputum induction in the setting of CF, and short-term studies have shown improved pulmonary function following treatment [154,155]. Recently it has been shown in a mouse model post thermal injury that hypertonic saline enhances host defense to bacterial challenge by augmenting TLRs [156]. Nebulised hypertonic saline, although a different mode of delivery and for a different purpose, may in fact work in a similar way.

Dornase alfa, a DNase, has been shown to reduce viscosity of sputum, allowing easier expectoration. Improvements in lung function have also been documented [157,158]. Viscosity is decreased by enzymatic degradation of host and bacterial DNA, with the added advantage that TLR9-mediated signalling in response to uCpG DNA is likely to be abrogated also.

8.3 Delivery of agents to the CF lung

The mucus lining the airways of the CF lungs is a complex biological environment posing significant barriers to efficient therapeutic drug delivery. CF mucus, which acts as the primary extracellular barrier in the CF lung contains mucin fibres that form a dense matrix intertwined with other macromolecules such as actin and DNA that decrease its permeability. The viscoelasticity of CF sputum greatly reduces the diffusion rates of colloidal particles, limiting the effectiveness of drug delivery to underlying lung cells. According to Dawson *et al.* [159], nanoparticles dispersed in CF sputum are transported primarily through lower viscosity pores within a highly elastic matrix. Neutral particles with a diameter of less than 200 nm undergo more rapid transport in CF sputum than charged or larger particles. Whilst DNase can reduce the macro-viscoelastic properties of CF sputum by up to 50% by hydrolyzing chromosomal DNA released from dead neutrophils, surprisingly, it does not significantly alter the average particle diffusion rate. This is most probably due an increased microviscosity [160].

Polyethylene glycol (PEG)ylated poly-L-lysine nanoparticles have been used to efficiently transfect lung epithelium following intrapulmonary administration [161]. This technology could assist any inhaled therapeutic in penetrating the airways.

9. Concluding remarks

As a major portal of entry for bacteria and microbes, the lung represents a key component of the innate immune system. Airborne pathogens encounter a number of effective defense mechanisms designed to rapidly counteract potential damage, inhibit colonization and protect against invasion by pathogens. The existence of TLRs equips the lung with an exquisitely designed mechanism for controlling microbial infection. Unfortunately CF is a disease in which the lung is so badly affected that innate immunity and TLR activity are dysfunctional. Thus, modulation of TLR function has obvious important implications. Enhancing TLR responses using targeted approaches directed at TLR3 could accelerate antiviral responses. Conversely suppression of other TLR responses, by the use of appropriate inhibitors could reduce the chronic inflammation characteristic of this disease. Thus, new therapeutics designed to selectively activate or inhibit TLR function specifically and reversibly represent powerful tools for the prevention and treatment of the pulmonary inflammatory manifestations of CF.

10. Expert opinion

TLR-targeted approaches to the management of inflammation and infection in CF differ with respect to bacterial and viral factors. In chronic bacterial colonization, as seen in CF, the problem is partly one of an overexuberant inflammatory response, which may need to be dampened down or be made

more effective in clearing bacteria. With respect to viral infection the focus is on enhancing rather than inhibiting type I interferon production in an attempt to eliminate the virus as soon as possible. Thus, the challenge is to design appropriate TLR-directed therapeutics with selective properties. In this regard designing drugs that activate or interfere with components of the signalling pathways rather than the TLRs themselves would appear to be the more targeted strategy. Progress in this area will be guided by the emerging knowledge regarding the mechanisms by which endogenous and microbial antagonists of TLR signalling exert their effects at a molecular level.

Manipulation of TLR signalling has inherent risks that must be carefully considered. Immunosuppression in the face of constant bacterial and fungal challenge may allow spread of infection and involvement of previously undamaged lung tissue. Therefore, until such time as we know the level of inflammation required to confine infection we must be conservative in our immunosuppressive approaches and any new trials must include careful monitoring of sputum organisms, inflammatory mediators, lung function and structural changes. Currently we are at a point where we are faced with determining how best to identify and minimize adverse events. By studying patients with known deficiencies in TLR signalling (e.g IRAK-4 [162]), we may be able to identify pathway-specific events that represent hallmarks of adverse suppressive effects. The corollary to this exists when attempting to enhance TLR function. Immunostimulatory therapies can create an undesirable 'hypercytokine' milieu. Data from animal studies will help to decipher such events. Indeed impairing antiviral immunity may actually confer an unexpected benefit as per the recent demonstration of an unexpected survival advantage in influenza-virus-infected mice deficient in TLR3, despite higher viral production in the lungs [163]. Thus, on balance, given that CF airways have aberrantly high cytokine levels even in the absence of detectable microbial infection, TLRs antagonists would appear to be the way forward.

With respect to existing conventional therapies there is evidence that many of these approaches directly or indirectly affect TLR-mediated responses and that their efficacy is mediated by this. We can learn a lot from current conventional therapies. We have seen that many of these, for example azithromycin or hypertonic saline exert their effects at least partly via TLRs. By understanding in more detail how these modulate the activity of TLRs to good effect we can design TLR-directed interventions that selectively inhibit the inflammatory part of the cascade whilst retaining the antimicrobial component. As with all therapeutic approaches for CF our enthusiasm for success must be tempered with a degree of caution. Important considerations for effective therapies, for example the use of A1AT augmentation therapy, or indeed any antiprotease therapy, designed to treat the pulmonary manifestations of CF include effective deposition in poorly aerated areas and protection against degradation and inactivation by serine and cysteinyl cathepsins present

784 in the CF airways. These challenges must remain at the
785 forefront of our scientific and clinical thinking.

Health Research Board, the CF Hope Source, the CF 791
Association of Ireland and Molecular Medicine Ireland.

Acknowledgements

790 Cystic fibrosis research in this laboratory is generously funded
by the Programme for Research in Third level Institutes, the

Declaration of interest

The authors declare no conflicts of interest and have received
no payment for the production of this manuscript. 797

Bibliography

Papers of special note have been highlighted
as either of interest (•) or of considerable
interest (••) to readers.

1. Tsui LC, Buchwald M. Biochemical and molecular genetics of cystic fibrosis. *Adv Hum Genet* 1991;20:153-266,311-2
2. Welsh MJ, Fick RB. Cystic fibrosis. *J Clin Invest* 1987;80(6):1523-6
3. Hoiby N. Cystic fibrosis and endobronchial *Pseudomonas* infection. *Curr Opin Pediatr* 1993;5(3):247-54
4. Davis PB. Cystic fibrosis since 1938. *Am J Respir Crit Care Med* 2006;173(5):475-82
- **A comprehensive review of the history of cystic fibrosis over the last 70 years.**
5. Lemaitre B, Nicolas E, Michaut L, et al. The dorsoventral regulatory gene cassette *sp.ätzle/Toll/cactus* controls the potent antifungal response in *Drosophila* adults. *Cell* 1996;86(6):973-83
6. Gay NJ, Keith FJ. *Drosophila*. Toll and IL-1 receptor. *Nature* 1991;351(6325):355-6
- **The first report, to our knowledge, of sequence similarity between *Drosophila* Toll and human IL-1R1.**
7. Akira S, Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. *Immunol Lett* 2003;85(2):85-95
8. O'Neill LA, Greene C. Signal transduction pathways activated by the IL-1 receptor family: ancient signaling machinery in mammals, insects, and plants. *J Leukoc Biol* 1998;63(6):650-7
9. O'Neill LA. Signal transduction pathways activated by the IL-1 receptor/toll-like receptor superfamily. *Curr Top Microbiol Immunol* 2002;270:47-61
10. Bell JK, Mullen GE, Leifer CA, et al. Leucine-rich repeats and pathogen recognition in Toll-like receptors. *Trends Immunol* 2003;24(10):528-33
11. Poltorak A, He X, Smirnova I, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in *Tlr4* gene. *Science* 1998;282(5396):2085-8
- **A key paper linking mutations in TLR4 to LPS hyporesponsiveness.**
12. Malley R, Henneke B, Morse SC, et al. Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. *Proc Natl Acad Sci USA* 2003;100(4):1966-71
13. Gomi K, Kawasaki K, Kawai Y, et al. Toll-like receptor 4-MD-2 complex mediates the signal transduction induced by flavolipin, an amino acid-containing lipid unique to *Flavobacterium meningosepticum*. *J Immunol* 2002;168(6):2939-43
14. Kurt-Jones EA, Popova L, Kwinn L, et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. *Nat Immunol* 2000;1(5):398-401
15. Rassa JC, Meyers JL, Zhang Y, et al. Murine retroviruses activate B cells via interaction with toll-like receptor 4. *Proc Natl Acad Sci USA* 2002;99(4):2281-6
16. Sasu S, LaVerda D, Qureshi N, et al. Chlamydia pneumoniae and chlamydial heat shock protein 60 stimulate proliferation of human vascular smooth muscle cells via toll-like receptor 4 and p44/p42 mitogen-activated protein kinase activation. *Circ Res* 2001;89(3):244-50
17. Jiang D, Liang J, Fan J, et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. *Nat Med* 2005;11(11):1173-9
- **Evidence is presented that non-microbial TLR agonists exist.**
18. Devaney JM, Greene CM, Taggart CC, et al. Neutrophil elastase up-regulates interleukin-8 via toll-like receptor 4. *FEBS Lett* 2003;544(1-3):129-32
19. Armstrong L, Medford AR, Uppington KM, et al. Expression of functional toll-like receptor-2 and -4 on alveolar epithelial cells. *Am J Respir Cell Mol Biol* 2004;31(2):241-5
20. Chu HW, Jeyaseelan S, Rino JG, et al. TLR2 signaling is critical for *Mycoplasma pneumoniae*-induced airway mucin expression. *J Immunol* 2005;174(9):5713-9
21. Gon Y, Asai Y, Hashimoto S, et al. A20 inhibits toll-like receptor 2- and 4-mediated interleukin-8 synthesis in airway epithelial cells. *Am J Respir Cell Mol Biol* 2004;31(3):330-6
22. Wetzler LM. The role of Toll-like receptor 2 in microbial disease and immunity. *Vaccine* 2003;21(Suppl 2):S55-60
23. Schmeck B, Huber S, Moog K, et al. Pneumococci induced TLR- and Rac1-dependent NF-κB-recruitment to the IL-8 promoter in lung epithelial cells. *Am J Physiol Lung Cell Mol Physiol* 2006;290(4):L730-7
24. Takeuchi O, Kawai T, Muhlrath PF, et al. Discrimination of bacterial lipoproteins by Toll-like receptor 6. *Int Immunol* 2001;13(7):933-40
25. Adamo R, Sokol S, Soong G, et al. *Pseudomonas aeruginosa* flagella activate airway epithelial cells through asialoGM1 and toll-like receptor 2 as well as toll-like receptor 5. *Am J Respir Cell Mol Biol* 2004;30(5):627-34
26. Hewson CA, Jardine A, Edwards MR, et al. Toll-like receptor 3 is induced by and mediates antiviral activity against rhinovirus infection of human bronchial epithelial cells. *J Virol* 2005;79(19):12273-9
27. Ritter M, Mennerich D, Weith A, et al. Characterization of Toll-like receptors in primary lung epithelial cells: strong impact of the TLR3 ligand poly(I:C) on the regulation of Toll-like receptors, adaptor proteins and inflammatory response. *J Inflamm (Lond)* 2005;2(1):16
28. Mayer AK, Muehmer M, Mages J, et al. Differential recognition of TLR-dependent microbial ligands in human bronchial epithelial cells. *J Immunol* 2007;178(5):3134-42
29. Hemmi H, Kaisho T, Takeuchi O, et al. Small anti-viral compounds activate immune cells via the TLR7

- MyD88-dependent signaling pathway. *Nat Immunol* 2002;3(2):196-200
30. Jurk M, Heil F, Vollmer J, et al. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. *Nat Immunol* 2002;3(6):499
 31. Diebold SS, Kaisho T, Hemmi H, et al. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. *Science* 2004;303(5663):1529-31
 32. Heil F, Hemmi H, Hochrein H, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. *Science* 2004;303(5663):1526-9
 33. Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. *Nature* 2000;408(6813):740-5
 - **This paper describes the identification of TLR9 as the receptor responsible for activation by unmethylated CpG dinucleotide motifs.**
 34. Hayashi F, Smith KD, Ozinsky A, et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. *Nature* 2001;410(6832):1099-103
 35. Hawn TR, Verbon A, Lettinga KD, et al. A common dominant TLR5 stop codon polymorphism abolishes flagellin signaling and is associated with susceptibility to legionnaires' disease. *J Exp Med* 2003;198(10):1563-72.
 36. Lopez-Boado YS, Cobb LM, Deora R. Bordetella. bronchiseptica. flagellin is a proinflammatory determinant for airway epithelial cells. *Infect Immun* 2005;73(11):7525-34
 37. Sadikot RT, Blackwell TS, Christman JW, et al. Pathogen-host interactions in *Pseudomonas. aeruginosa. pneumonia.* *Am J Respir Crit Care Med* 2005;171(11):1209-23
 38. Zhang Z, Louboutin JP, Weiner DJ, et al. Human airway epithelial cells sense *Pseudomonas. aeruginosa. infection* via recognition of flagellin by Toll-like receptor 5. *Infect Immun* 2005;73(11):7151-60
 39. Hasan U, Chaffois C, Gaillard C, et al. Human TLR10 is a functional receptor, expressed by B cells and plasmacytoid dendritic cells, which activates gene transcription through MyD88. *J Immunol* 2005;174(5):2942-50
 40. Yamamoto M, Takeda K, Akira S. TIR domain-containing adaptors define the specificity of TLR signaling. *Mol Immunol* 2004;40(12):861-8
 41. Akira S, Takeda K. Toll-like receptor signalling. *Nat Rev Immunol* 2004;4(7):499-511
 42. Yamamoto M, Sato S, Hemmi H, et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. *Science* 2003;301(5633):640-3
 43. Schroder NW, Pfeil D, Opitz B, et al. Activation of mitogen-activated protein kinases p42/44, p38, and stress-activated protein kinases in myelo-monocytic cells by *Treponema lipoteichoic acid.* *J Biol Chem* 2001;276(13):9713-9
 44. Nagai Y, Akashi S, Nagafuku M, et al. Essential role of MD-2 in LPS responsiveness and TLR4 distribution. *Nat Immunol* 2002;3(7):667-72
 45. Chow JC, Young DW, Golenbock DT, et al. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. *J Biol Chem* 1999;274(16):10689-92
 46. Medzhitov R, Preston-Hurlburt P, Kopp E, et al. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. *Mol Cell* 1998;2(2):253-8
 47. Fitzgerald KA, Palsson-McDermott EM, Bowie AG et al. Mal (MyD88-adaptor-like) is required for Toll-like receptor-4 signal transduction. *Nature* 2001;413(6851):78-83
 48. Horng T, Barton GM, Medzhitov R. TIRAP: an adapter molecule in the Toll signaling pathway. *Nat Immunol* 2001;2(9):835-41
 49. Oshiumi H, Matsumoto M, Funami K, et al. TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon- β induction. *Nat Immunol* 2003;4(2):161-7
 50. Fitzgerald KA, Rowe DC, Barnes BJ, et al. LPS-TLR4 signaling to IRF-3/7 and NF- κ B involves the toll adapters TRAM and TRIF. *J Exp Med* 2003;198(7):1043-55
 51. Oshiumi H, Sasai M, Shida K, et al. TIR-containing adapter molecule (TICAM)-2, a bridging adapter recruiting to toll-like receptor 4 TICAM-1 that induces interferon- β . *J Biol Chem* 2003;278(50):49751-62
 52. Yamamoto M, Sato S, Hemmi H et al. TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway. *Nat Immunol* 2003;4(11):1144-50
 53. Suzuki N, Suzuki S, Duncan GS, et al. Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4. *Nature* 2002;416(6882):750-6
 - **The first report, to our knowledge, linking mutations in TLR signalling proteins to dysfunctional innate immune responses.**
 54. Deng L, Wang C, Spencer E, et al. Activation of the I κ B kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. *Cell* 2000;103(2):351-61
 55. Wang C, Deng L, Hong M, et al. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. *Nature* 2001;412(6844):346-51
 56. Kawai T, Takeuchi O, Fujita T, et al. Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. *J Immunol* 2001;167(10):5887-94
 - **This paper reports the identification of IRF3 as a TLR4-inducible transcription factor.**
 57. Sharma S, tenOever BR, Grandvaux N, et al. Triggering the interferon antiviral response through an IKK-related pathway. *Science* 2003;300(5622):1148-51
 58. Greene CM, Carroll TP, Smith SG, et al. TLR-Induced inflammation in cystic fibrosis and non-cystic fibrosis airway epithelial cells. *J Immunol* 2005;174(3):1638-46
 - **The paper evaluates multiple TLR-induced signalling events and cytokine production in CF and non-CF airway epithelial cells.**
 59. Guillot L, Medjane S, Le-Barillec K, et al. Response of human pulmonary epithelial cells to lipopolysaccharide involves Toll-like receptor 4 (TLR4)-dependent signaling pathways: evidence for an intracellular compartmentalization of TLR4. *J Biol Chem* 2004;279(4):2712-8
 60. Carroll TP, Greene CM, Taggart CC, et al. Viral inhibition of IL-1- and neutrophil elastase-induced inflammatory responses in bronchial epithelial cells. *J Immunol* 2005;175(11):7594-601
 - **A demonstration of the effect of Vaccinia Virus TLR antagonists on neutrophil elastase-induced NF- κ B activation and cytokine production in human bronchial epithelial cells.**
 61. Homma T, Kato A, Hashimoto N, et al. Corticosteroid and cytokines synergistically enhance toll-like receptor 2 expression in

- respiratory epithelial cells. *Am J Respir Cell Mol Biol* 2004;31(4):463-9
62. Monick MM, Yarovsky TO, Powers LS, et al. Respiratory syncytial virus up-regulates TLR4 and sensitizes airway epithelial cells to endotoxin. *J Biol Chem* 2003;278(52):53035-44
63. Sha Q, Truong-Tran AQ, Plitt JR, et al. Activation of airway epithelial cells by toll-like receptor agonists. *Am J Respir Cell Mol Biol* 2004;31(3):358-64
64. Hertz CJ, Wu Q, Porter EM, et al. Activation of Toll-like receptor 2 on human tracheobronchial epithelial cells induces the antimicrobial peptide human beta defensin-2. *J Immunol* 2003;171(12):6820-6
65. Wang X, Zhang Z, Louboutin JP, et al. Airway epithelia regulate expression of human β -defensin 2 through Toll-like receptor 2. *FASEB J* 2003;17(12):1727-9
66. Jia HP, Kline JN, Penisten A, et al. Endotoxin responsiveness of human airway epithelia is limited by low expression of MD-2. *Am J Physiol Lung Cell Mol Physiol* 2004;287(2):L428-37
67. Ohashi K, Burkart V, Flohe S, et al. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. *J Immunol* 2000;164(2):558-61
68. Okamura Y, Watari M, Jerud ES, et al. The extra domain A of fibronectin activates Toll-like receptor 4. *J Biol Chem* 2001;276(13):10229-33
69. Taylor KR, Trowbridge JM, Rudisill JA, et al. Hyaluronan fragments stimulate endothelial recognition of injury through TLR4. *J Biol Chem* 2004;279(17):17079-84
70. Vabulas RM, Ahmad-Nejad P, Ghose S, et al. HSP70 as endogenous stimulus of the Toll/interleukin-1 receptor signal pathway. *J Biol Chem* 2002;277(17):15107-12
71. Vabulas RM, Braedel S, Hilf N, et al. The endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via the Toll-like receptor 2/4 pathway. *J Biol Chem* 2002;277(23):20847-53
72. Frantz S, Kelly RA, Bourcier T. Role of TLR-2 in the activation of nuclear factor κ B by oxidative stress in cardiac myocytes. *J Biol Chem* 2001;276(7):5197-203
73. Chaudhuri N, Dower SK, Whyte MK, et al. Toll-like receptors and chronic lung disease. *Clin Sci (Lond)* 2005;109(2):125-33
74. Syhre M, Scotter JM, Chambers ST. Investigation into the production of 2-Pentylfuran by *Aspergillus fumigatus* and other respiratory pathogens in vitro and human breath samples. *Med Mycol* 2008;46(3):209-15
75. Schwartz DA, Quinn TJ, Thorne PS, et al. CpG motifs in bacterial DNA cause inflammation in the lower respiratory tract. *J Clin Invest* 1997;100(1):68-73
- **A demonstration of high levels of DNA in CF lung.**
76. Wang EE, Prober CG, Manson B, et al. Association of respiratory viral infections with pulmonary deterioration in patients with cystic fibrosis. *N Engl J Med* 1984;311(26):1653-8
77. Abman SH, Ogle JW, Butler-Simon N, et al. Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis. *J Pediatr* 1988;113(5):826-30
78. Smyth AR, Smyth RL, Tong CY, et al. Effect of respiratory virus infections including rhinovirus on clinical status in cystic fibrosis. *Arch Dis Child* 1995;73(2):117-20
79. Hiatt PW, Grace SC, Kozinetz CA, et al. Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis. *Pediatrics* 1999;103(3):619-26
80. Abman SH, Ogle JW, Harbeck RJ, et al. Early bacteriologic, immunologic, and clinical courses of young infants with cystic fibrosis identified by neonatal screening. *J Pediatr* 1991;119(2):211-7
81. Armstrong D, Grimwood K, Carlin JB, et al. Severe viral respiratory infections in infants with cystic fibrosis. *Pediatr Pulmonol* 1998;26(6):371-9
82. Mastrorade JG, Monick MM, Hunninghake GW. Oxidant tone regulates IL-8 production in epithelium infected with respiratory syncytial virus. *Am J Respir Cell Mol Biol* 1995;13(2):237-44
83. Ohnui T, Yamaya M, Sekizawa K, et al. Effects of rhinovirus infection on hydrogen peroxide-induced alterations of barrier function in the cultured human tracheal epithelium. *Am J Respir Crit Care Med* 1998;158(1):241-8
84. Walsh JJ, Dietlein LF, Low FN, et al. Bronchotracheal response in human influenza. Type A, Asian strain, as studied by light and electron microscopic examination of bronchoscopic biopsies. *Arch Intern Med* 1961;108:376-88
85. Winther B, Gwaltney JM, Hendley JO. Respiratory virus infection of monolayer cultures of human nasal epithelial cells. *Am Rev Respir Dis* 1990;141(4 Pt 1):839-45
86. Hament JM, Kimpen JL, Fleer A, et al. Respiratory viral infection predisposing for bacterial disease: a concise review. *FEMS Immunol Med Microbiol* 1999;26(3-4):189-95
87. Van Ewijk BE, Wolfs TF, Aerts PC, et al. RSV mediates *Pseudomonas aeruginosa* binding to cystic fibrosis and normal epithelial cells. *Pediatr Res* 2007;61(4):398-403
88. Oliver BG, Lim S, Wark P, et al. Rhinovirus exposure impairs immune responses to bacterial products in human alveolar macrophages. *Thorax* 2008;63(6):519-25
89. Dharmaj P, Tan A, Smyth R. Vaccines for preventing influenza in people with cystic fibrosis. *Cochrane Database Syst Rev* 2000(2):CD001753. Published online 24 January 2000, doi:10.1002/14651858.CD001753
90. Wat D, Gelder C, Hibbitts S, et al. Is there a role for influenza vaccination in cystic fibrosis? *J Cyst Fibros* 2008;7(1):85-8
91. Fiore AE, Shay DK, Haber P, et al. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. *MMWR Recomm Rep* 2007;56(RR-6):1-54
92. Antiviral therapy and prophylaxis for influenza in children. *Pediatrics* 2007;119(4):852-60
93. O'Reilly SM, Moynagh PN. Regulation of Toll-like receptor 4 signalling by A20 zinc finger protein. *Biochem Biophys Res Commun* 2003;303(2):586-93
94. Boone DL, Turer EE, Lee EG, et al. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. *Nat Immunol* 2004;5(10):1052-60
95. Yokota S, Okabayashi T, Yokosawa N, et al. Measles virus P protein suppresses Toll-like receptor signal through up-regulation of ubiquitin-modifying enzyme A20. *FASEB J* 2008;22(1):74-83
96. Burns K, Clatworthy J, Martin L, et al. Tollip, a new component of the IL-1RI pathway, links IRAK to the IL-1 receptor. *Nat Cell Biol* 2000;2(6):346-51

97. Zhang G, Ghosh S. Negative regulation of toll-like receptor-mediated signaling by Tollip. *J Biol Chem* 2002;277(9):7059-65
98. Mantovani A, Locati M, Polentarutti N, et al. Extracellular and intracellular decoys in the tuning of inflammatory cytokines and Toll-like receptors: the new entry TIR8/SIGIRR. *J Leukoc Biol* 2004;75(5):738-42
99. Burns K, Janssens S, Brissoni B, et al. Inhibition of interleukin 1 receptor/Toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4. *J Exp Med* 2003;197(2):263-8
100. Wesche H, Gao X, Li X, et al. IRAK-M is a novel member of the Pelle/interleukin-1 receptor-associated kinase (IRAK) family. *J Biol Chem* 1999;274(27):19403-10
101. Kobayashi K, Hernandez LD, Galan JE, et al. IRAK-M is a negative regulator of Toll-like receptor signaling. *Cell* 2002;110(2):191-202
102. Rothlin CV, Ghosh S, Zuniga EI, et al. TAM receptors are pleiotropic inhibitors of the innate immune response. *Cell* 2007;131(6):1124-36
103. Carty M, Goodbody R, Schroder M, et al. The human adaptor SARM negatively regulates adaptor protein TRIF-dependent Toll-like receptor signaling. *Nat Immunol* 2006;7(10):1074-81
- **This paper identifies the adaptor protein SARM as a negative regulator of TLR signalling.**
104. An H, Hou J, Zhou J, et al. Phosphatase SHP-1 promotes TLR- and RIG-I-activated production of type I interferon by inhibiting the kinase IRAK1. *Nat Immunol* 2008;9(5):542-50
- **A key paper reporting how the phosphatase SHP-1 controls expression of TLR-induced IL-8 or IFN at the level of IRAK.**
105. Xu H, An H, Hou J, et al. Phosphatase PTP1B negatively regulates MyD88- and TRIF-dependent proinflammatory cytokine and type I interferon production in TLR-triggered macrophages. *Mol Immunol* 2008;45(13):3545-52
106. Kato K, Lu W, Kai H, et al. Phosphoinositide 3-kinase is activated by MUC1 but not responsible for MUC1-induced suppression of Toll-like receptor 5 signaling. *Am J Physiol Lung Cell Mol Physiol* 2007;293(3):L686-92
107. Ueno K, Koga T, Kato K, et al. MUC1 mucin is a negative regulator of toll-like receptor signaling. *Am J Respir Cell Mol Biol* 2008;38(3):263-8
108. Appel S, Mirakaj V, Bringmann A, et al. PPAR- γ agonists inhibit toll-like receptor-mediated activation of dendritic cells via the MAP kinase and NF- κ B pathways. *Blood* 2005;106(12):3888-94
109. Bowie A, Kiss-Toth E, Symons JA, et al. A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling. *Proc Natl Acad Sci USA* 2000;97(18):10162-7
110. Stack J, Haga IR, Schroder M, et al. Vaccinia virus protein A46R targets multiple Toll-like-interleukin-1 receptor adaptors and contributes to virulence. *J Exp Med* 2005;201(6):1007-18
111. DiPerna G, Stack J, Bowie AG, et al. Poxvirus protein N1L targets the I- κ B kinase complex, inhibits signaling to NF- κ B by the tumor necrosis factor superfamily of receptors, and inhibits NF- κ B and IRF3 signaling by toll-like receptors. *J Biol Chem* 2004;279(35):36570-8
112. Shingai M, Azuma M, Ebihara T, et al. Soluble G protein of respiratory syncytial virus inhibits Toll-like receptor 3/4-mediated IFN- β induction. *Int Immunol* 2008;20(9):1169-80
- **Identification of a RSV factor that acts as a TLR3/4 antagonist.**
113. Newman RM, Salunkhe P, Godzik A, et al. Identification and characterization of a novel bacterial virulence factor that shares homology with mammalian Toll/interleukin-1 receptor family proteins. *Infect Immun* 2006;74(1):594-601
114. Salcedo SP, Marchesini MI, Lelouard H, et al. Brucella control of dendritic cell maturation is dependent on the TIR-containing protein Btp1. *PLoS Pathog* 2008;4(2):e21. Published online 8 February 2008, doi:10.1371/journal.ppat.0040021
115. Cirl C, Wieser A, Yadav M, et al. Subversion of Toll-like receptor signaling by a unique family of bacterial Toll/interleukin-1 receptor domain-containing proteins. *Nat Med* 2008;14(4):399-406
116. Bartfai T, Behrens MM, Gaidarova S, et al. A low molecular weight mimic of the Toll/IL-1 receptor/resistance domain inhibits IL-1 receptor-mediated responses. *Proc Natl Acad Sci USA* 2003;100(13):7971-6
117. Davis CN, Mann E, Behrens MM, et al. MyD88-dependent and -independent signaling by IL-1 in neurons probed by bifunctional Toll/IL-1 receptor domain/BB-loop mimetics. *Proc Natl Acad Sci USA* 2006;103(8):2953-8
118. Toshchakov VY, Vogel SN. Cell-penetrating TIR BB loop decoy peptides a novel class of TLR signaling inhibitors and a tool to study topology of TIR-TIR interactions. *Expert Opin Biol Ther* 2007;7(7):1035-50
- **This paper presents a comprehensive approach to inhibit TLR signalling using inhibitory peptides based on the structure of the TIR domain.**
119. Thompson RC, Ohlsson K. Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase. *Proc Natl Acad Sci USA* 1986;83(18):6692-6
120. Bingle L, Tetley TD. Secretory leukoprotease inhibitor: partnering α_1 -proteinase inhibitor to combat pulmonary inflammation. *Thorax* 1996;51(12):1273-4
121. Doumas S, Kolokotronis A, Stefanopoulos P. Anti-inflammatory and antimicrobial roles of secretory leukocyte protease inhibitor. *Infect Immun* 2005;73(3):1271-4
122. Hiemstra PS, Fernie-King BA, McMichael J, et al. Antimicrobial peptides: mediators of innate immunity as templates for the development of novel anti-infective and immune therapeutics. *Curr Pharm Des* 2004;10(23):2891-905
123. Williams SE, Brown TI, Roghanian A, et al. SLPI and elafin: one glove, many fingers. *Clin Sci (Lond)* 2006;110(1):21-35
124. Wiedow O, Harder J, Bartels J, et al. Antileukoprotease in human skin: an antibiotic peptide constitutively produced by keratinocytes. *Biochem Biophys Res Commun* 1998;248(3):904-9
125. McNeely TB, Dealy M, Dripps DJ, et al. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro *J Clin Invest* 1995;96(1):456-64
126. Greene CM, McElvaney NG, O'Neill SJ, et al. Secretory leukoprotease inhibitor impairs Toll-like receptor 2- and 4-mediated responses in monocytic cells. *Infect Immun* 2004;72(6):3684-7

127. Jin F, Nathan CF, Radzioch D, et al. Lipopolysaccharide-related stimuli induce expression of the secretory leukocyte protease inhibitor, a macrophage-derived lipopolysaccharide inhibitor. *Infect Immun* 1998;66(6):2447-52
128. Taggart CC, Greene CM, McElvaney NG, et al. Secretory leucoprotease inhibitor prevents lipopolysaccharide-induced I κ B α degradation without affecting phosphorylation or ubiquitination. *J Biol Chem* 2002;277(37):33648-53
129. Taggart CC, Cryan SA, Weldon S, et al. Secretory leucoprotease inhibitor binds to NF- κ B binding sites in monocytes and inhibits p65 binding. *J Exp Med* 2005;202(12):1659-68
- **This paper describes the mechanism by which SLPI can inhibit p65 binding to NF κ B sites in the promoter of TLR-responsive genes.**
130. Tomee JF, Hiemstra PS, Heinzl-Wieland R, et al. Antileukoprotease: an endogenous protein in the innate mucosal defense against fungi. *J Infect Dis* 1997;176(3):740-7
131. Tomee JF, Wierenga AT, Hiemstra PS, et al. Proteases from *Aspergillus fumigatus* induce release of proinflammatory cytokines and cell detachment in airway epithelial cell lines. *J Infect Dis* 1997;176(1):300-3
132. Griffin S, Carroll TP, Greene CM, et al. Effect of pro-inflammatory stimuli on mucin expression and inhibition by secretory leucoprotease inhibitor. *Cell Microbiol* 2007;9(3):670-9
133. Sallenave JM, Marsden MD, Ryle AP. Isolation of elafin and elastase-specific inhibitor (ESI) from bronchial secretions. Evidence of sequence homology and immunological cross-reactivity. *Biol Chem Hoppe Seyler* 1992;373(1):27-33
134. Guyot N, Zani ML, Berger P, et al. Proteolytic susceptibility of the serine protease inhibitor trappin-2 (pre-elafin): evidence for tryptase-mediated generation of elafin. *Biol Chem* 2005;386(4):391-9
135. Sallenave JM, Shulmann J, Crossley J, et al. Regulation of secretory leukocyte proteinase inhibitor (SLPI) and elastase-specific inhibitor (ESI/elafin) in human airway epithelial cells by cytokines and neutrophilic enzymes. *Am J Respir Cell Mol Biol* 1994;11(6):733-41
136. Butler MW, Robertson I, Greene CM, et al. Elafin prevents lipopolysaccharide-induced AP-1 and NF- κ B activation via an effect on the ubiquitin-proteasome pathway. *J Biol Chem* 2006;281(46):34730-5
137. Baranger K, Zani ML, Chandenier J, et al. The antibacterial and antifungal properties of trappin-2 (pre-elafin) do not depend on its protease inhibitory function. *FEBS J* 2008;275(9):2008-20
- **A report of elafin's antimicrobial properties.**
138. Janciauskiene S, Larsson S, Larsson P, et al. Inhibition of lipopolysaccharide-mediated human monocyte activation, in vitro, by α 1-antitrypsin. *Biochem Biophys Res Commun* 2004;321(3):592-600
139. Subramaniam D, Glader P, von Wachenfeldt K, et al. C-36 peptide, a degradation product of α 1-antitrypsin, modulates human monocyte activation through LPS signaling pathways. *Int J Biochem Cell Biol* 2006;38(4):563-75
140. Matthews LW, Doershuk CF. Inhalation therapy and postural drainage for the treatment of cystic fibrosis. *Bibl Paediatr* 1967;86:297-314
141. Spencer LT, Humphries JE, Brantly ML. Antibody response to aerosolized transgenic human α 1-antitrypsin. *N Engl J Med* 2005;352(19):2030-1
142. Kudoh S, Azuma A, Yamamoto M, et al. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. *Am J Respir Crit Care Med* 1998;157(6 Pt 1):1829-32
143. Wolter J, Seeney S, Bell S, et al. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. *Thorax* 2002;57(3):212-6
144. Equi A, Balfour-Lynn IM, Bush A, et al. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. *Lancet* 2002;360(9338):978-84
145. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with *Pseudomonas aeruginosa*: a randomized controlled trial. *Jama* 2003;290(13):1749-56
146. Saiman L. The use of macrolide antibiotics in patients with cystic fibrosis. *Curr Opin Pulm Med* 2004;10(6):515-23
147. Cigana C, Assael BM, Melotti P. Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells. *Antimicrob Agents Chemother* 2007;51(3):975-81
148. Aghai ZH, Kode A, Saslow JG, et al. Azithromycin suppresses activation of nuclear factor-kappa B and synthesis of pro-inflammatory cytokines in tracheal aspirate cells from premature infants. *Pediatr Res* 2007;62(4):483-8
- **Evidence is presented on azithromycin's anti-inflammatory properties *ex vivo* in infants with bronchopulmonary dysplasia.**
149. Ivetic Tkalecic V, Bosnjak B, Hrvacic B, et al. Anti-inflammatory activity of azithromycin attenuates the effects of lipopolysaccharide administration in mice. *Eur J Pharmacol* 2006;539(1-2):131-8
150. Kawamura-Sato K, Iinuma Y, Hasegawa T, et al. Effect of subinhibitory concentrations of macrolides on expression of flagellin in *Pseudomonas aeruginosa* and *Proteus mirabilis*. *Antimicrob Agents Chemother* 2000;44(10):2869-72
151. Kawamura-Sato K, Iinuma Y, Hasegawa T, et al. Postantibiotic suppression effect of macrolides on the expression of flagellin in *Pseudomonas aeruginosa* and *Proteus mirabilis*. *J Infect Chemother* 2001;7(1):51-4
152. Matsui H, Eguchi M, Ohsumi K, et al. Azithromycin inhibits the formation of flagellar filaments without suppressing flagellin synthesis in *Salmonella enterica* serovar typhimurium. *Antimicrob Agents Chemother* 2005;49(8):3396-403
153. Rozkova D, Horvath R, Bartunkova J, et al. Glucocorticoids severely impair differentiation and antigen presenting function of dendritic cells despite upregulation of Toll-like receptors. *Clin Immunol* 2006;120(3):260-71
154. Eng PA, Morton J, Douglass JA, et al. Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. *Pediatr Pulmonol* 1996;21(2):77-83
155. Ballmann M, von der Hardt H. Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. *J Cyst Fibros* 2002;1(1):35-7
156. Chen LW, Huang HL, Lee IT, et al. Hypertonic saline enhances host defense to bacterial challenge by augmenting Toll-like receptors. *Crit Care Med* 2006;34(6):1758-68
157. Ranasinha C, Assoufi B, Shak S, et al. Efficacy and safety of short-term administration of aerosolised recombinant

- human DNase I in adults with stable stage cystic fibrosis. *Lancet* 1993;342(8865):199-202
158. Ramsey BW, Astley SJ, Aitken ML, et al. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. *Am Rev Respir Dis* 1993;148(1):145-51
 159. Dawson M, Wirtz D, Hanes J. Enhanced viscoelasticity of human cystic fibrotic sputum correlates with increasing microheterogeneity in particle transport. *J Biol Chem* 2003;278(50):50393-401
 160. Suh J, Dawson M, Hanes J. Real-time multiple-particle tracking: applications to drug and gene delivery. *Adv Drug Deliv Rev* 2005;57(1):63-78
 161. Fink TL, Klepcyk PJ, Oette SM, et al. Plasmid size up to 20 kbp does not limit effective in vivo lung gene transfer using compacted DNA nanoparticles. *Gene Ther* 2006;13(13):1048-51
 162. Ku CL, von Bernuth H, Picard C, et al. Selective predisposition to bacterial infections in IRAK-4-deficient children: IRAK-4-dependent TLRs are otherwise redundant in protective immunity. *J Exp Med* 2007;204(10):2407-22
 163. Le Goffic R, Balloy V, Lagranderie M, et al. Detrimental contribution of the Toll-like receptor (TLR)3 to influenza A virus-induced acute pneumonia. *PLoS Pathog* 2006;2(6):e53. Published online 9 June 2006, doi:10.1371/journal.ppat.0020053

Affiliation

Catherine M Greene^{†1} BA PhD,
Peter Branagan² MB BCH BAO &
Noel G McElvaney³ MB BCH BAO FRCPI

[†]Author for correspondence

¹Senior Lecturer in Medicine

Beaumont Hospital,

Education and Research Centre,

Royal College of Surgeons in Ireland,

Respiratory Research Division,

9 Dublin, Ireland

Tel: +01 8093712; Fax: +01 8093808;

E-mail: cmgreene@rcsi.ie

²Specialist Registrar in Respiratory Medicine

³Professor of Medicine and Consultant

Respiratory Physician